Stem Cell Authority, Ltd. (SCAL) Comparison with companies in other sectors?

Stem Cell Authority, Ltd. has a share price of 87.12M. You can analyze Stem Cell Authority, Ltd. (SCAL) competitors across different market sectors through stock heatmaps.

What are SCAL's NET and operating margins?

Stem Cell Authority, Ltd. (SCAL) operating margin is around 0.00, and net profit margin is approximately 0.00 as of the latest reports.

In what way does SCAL's earnings per share (EPS) trend reflect its financial momentum?

Stem Cell Authority, Ltd. (SCAL) EPS is 0.005 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Stem Cell Authority, Ltd. is 0.04, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Stem Cell Authority, Ltd.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Stem Cell Authority, Ltd. like P/E which is -45.87, P/B which is -2.41, and PEG which is -0.46. Compare them with sector averages to evaluate if the stock is priced fairly.

Stem Cell Authority, Ltd.

SCAL•PNK

Healthcare

Medical - Care Facilities

$0.00

$-0.00(-0.00%)

Fundamental Analysis of Stem Cell Authority, Ltd. (SCAL)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$0.005

P/E Ratio

0.04

ROE

0.07%

Net Margin

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$17.42K

Shares OutstandingTotal number of shares issued

$87.12M

Book Value/ShareNet worth per share

$-0.00

Revenue/ShareAnnual revenue per share

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.005

Net MarginNet income as percentage of revenue

Operating MarginOperating income as percentage of revenue

ROEReturn on shareholders' equity

7.07%

ROAReturn on total assets

-28220.00%

ROCEReturn on capital employed

5.25%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.00

Cash/ShareCash and equivalents per share

$0.00

FCF YieldFree cash flow as percentage of market cap

-231.35%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for SCALFinancial Ratios Analysis details for SCAL are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for SCALSector Benchmarking details for SCAL are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Stem Cell Authority, Ltd. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Stem Cell Authority, Ltd.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Stem Cell Authority, Ltd.'s unique business strengths and challenges.

Key Financial Metrics for Stem Cell Authority, Ltd.

For Stem Cell Authority, Ltd., essential financial indicators include EPS 0.005, PE 0.04, and ROE 0.07. These key ratios reveal insights into Stem Cell Authority, Ltd.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Stem Cell Authority, Ltd. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Stem Cell Authority, Ltd.

Metrics like Net Margin - and ROA -28220.00% shed light on how well Stem Cell Authority, Ltd. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Stem Cell Authority, Ltd. can sustain its operations and continue growing in the future.

Valuation and Market Position of Stem Cell Authority, Ltd.

Using ratios such as P/B Ratio -2.41 and PEG Ratio -0.46, investors can assess whether Stem Cell Authority, Ltd. is appropriately valued based on its financials and growth potential. These figures, combined with Stem Cell Authority, Ltd.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Stem Cell Authority, Ltd.

Financial health indicators, such as Debt/Equity Ratio - and Cash Flow $-0.00, provide a snapshot of Stem Cell Authority, Ltd.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Stem Cell Authority, Ltd., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Stem Cell Authority, Ltd.

Investing in Stem Cell Authority, Ltd. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Stem Cell Authority, Ltd. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;